Close

News

COVID-19: Potential Vaccines and Logistics

While pharmaceuticals contribute to approximately 2% of annual air cargo volume, the industry transports over one trillion dollars’ worth of cargo every year (IATA). Pharmaceutical shipments have an overwhelmingly large impact on the global response to infectious diseases and...

China grants country’s first Covid-19 vaccine patent to CanSino

China's vaccine maker CanSino Biologics Inc has won a patent approval from Beijing for its COVID-19 vaccine candidate Ad5-nCOV, People's Daily reported, citing documents from the country's intellectual property regulator. The patent was submitted for application on March 18,...

Covaxin: Bharat Biotech-ICMR developed vaccine is safe, show preliminary results

The preliminary results of phase 1 clinical trials of Bharat Biotech-ICMR developed Covaxin, a COVID-19 vaccine, has shown that the vaccine is safe. The results were informed by the principal investigators who have been conducting the trials of the...

Russia’s COVID-19 vaccine to enter production, deliver first batch of doses in two weeks

The world's first vaccine registered by Russian authorities, and now the World Health Organisation has said it is in talks with Russia's health ministry for a thorough review of the safety and efficacy of the vaccine, called Sputnik V. While...

TIACA and Pharma.Aero Join Forces to Prepare Air Cargo Industry for COVID-19 Vaccine

The International Air Cargo Association (TIACA) and Pharma.Aero have joined forces to develop global guidance for the air cargo industry to enable optimal transportation of the COVID-19 vaccine. The guidance will be developed gradually in four work packages through...

FDA Accepts Biogens Aducanumab Biologics License Application for Alzheimer’s Disease with Priority Review

Biogen and Eisai, Co., Ltd. announced that the U.S. FDA has accepted the Biologics License Application (BLA) for aducanumab, an investigational treatment for Alzheimer’s disease. The application has been granted Priority Review, with a Prescription Drug User Fee Act...

Caprion-HistoGeneX, Viroclinics-DDL Announce COVID-19 Research Partnership

Caprion-HistoGeneX and Viroclinics-DDL announced a new strategic partnership to expand their global capabilities addressing the emerging needs for therapeutic and prophylactic solutions to target infectious diseases including COVID-19. This partnership brings together the leadership of two contract research organizations...

Subscribe

- Never miss a story with notifications

- Gain full access to our premium content

- Browse free from any location or device.

Must read